Macrolide-resistant Bordetella pertussis infection in newborn girl, France

Emerg Infect Dis. 2012 Jun;18(6):966-8. doi: 10.3201/eid1806.120091.

Abstract

A macrolide antimicrobial drug was administered to a newborn with cough. On day 23 of hospitalization, macrolide-resistant Bordetella pertussis was isolated from nasopharyngeal aspirates. DNA sequencing and PCR-restriction fragment length polymorphism showed a 2047 A-to-G mutation in the 3 copies of the 23S rRNA gene. Monitoring for macrolide resistance is essential in infants <6 months of age.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use
  • Bordetella pertussis / drug effects*
  • Bordetella pertussis / genetics
  • Clarithromycin / pharmacology
  • Clarithromycin / therapeutic use
  • DNA Mutational Analysis
  • Drug Resistance, Bacterial*
  • Exchange Transfusion, Whole Blood
  • Female
  • Humans
  • Infant, Newborn
  • RNA, Ribosomal, 23S / genetics
  • Treatment Outcome
  • Whooping Cough / diagnosis*
  • Whooping Cough / therapy

Substances

  • RNA, Ribosomal, 23S
  • Azithromycin
  • Clarithromycin